Evidence map›Paper›PMID 41006771›Full record

ArticleScientific reports2025

LncRNA HOXA11-AS promotes the cell proliferation, migration, invasion and inhibits cell apoptosis in esophageal squamous cell carcinoma.

Wanwen Li, Shenglong Xie, Haiqi Liu, Wei Li, Bin He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wanwen Li *Department of Thoracic Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, Section 2, 1st Ring Road, Qingyang District, Chengdu, 610000, China.
Shenglong Xie *Department of Thoracic Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, Section 2, 1st Ring Road, Qingyang District, Chengdu, 610000, China.
Haiqi LiuDepartment of Thoracic Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, Section 2, 1st Ring Road, Qingyang District, Chengdu, 610000, China.
Wei LiDepartment of Thoracic Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, Section 2, 1st Ring Road, Qingyang District, Chengdu, 610000, China.
Bin HeDepartment of Thoracic Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 32, Section 2, 1st Ring Road, Qingyang District, Chengdu, 610000, China. sy99426@sina.com.

Funding

the Natural Science Foundation of Sichuan Province 2022NSFSC0780
6 · The paper itself

Abstract

This study aimed to investigate the expression and evaluate the function of long non-coding RNA (LncRNA) HOXA11-AS in Esophageal Squamous Cell Carcinoma (ESCC). HOXA11-AS expression was quantified in paired ESCC tumor tissues (n = 50) and adjacent histologically normal tissues (> 5 cm from tumor margin) (n=50) from surgical patients. The relationship between HOXA11-AS expression levels, clinical staging and patient survival was analyzed. Lentiviral transduction was employed to generate stable ESCC cell lines with HOXA11-AS overexpression (lv-HOXA11-AS) or knockdown (sh-HOXA11-AS), accompanied by negative control groups (lv-NC/sh-NC). The impact on malignant phenotype was assessed via CCK-8 proliferation assays, Transwell migration/invasion assays, wound healing assays, and flow cytometry for apoptosis. In vivo tumor growth was evaluated by subcutaneously injecting fluorescently labeled lv-HOXA11-AS or lv-NC cells into BALB/c-nu mice. RNA-sequencing and tissue qRT-PCR confirmed significantly higher HOXA11-AS expression in ESCC versus normal epithelium, and high HOXA11-AS expression was associated with advanced tumor stage and was identified as an independent predictor of poor prognosis. qRT-PCR validated the elevated expression of HOXA11-AS in ESCC cell lines too. HOXA11-AS overexpression promoted proliferation, migration, invasion, and suppressed early apoptosis in ESCC cells, HOXA11-AS knockdown exerted opposing effects. HOXA11-AS overexpression significantly enhanced tumor growth in mouse xenograft models. LncRNA HOXA11-AS is aberrantly overexpressed in ESCC and functions as an oncogene, driving tumor progression by enhancing proliferation, migration, invasion and suppressing apoptosis. Its association with poor prognosis identifies HOXA11-AS as a promising prognostic biomarker and potential therapeutic target for ESCC.

Indexed as

ApoptosisCell MovementEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaRNA, Long NoncodingAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred BALB CMice, NudeMiddle AgedRNA, Long NoncodingApoptosis of cellsCell migration and invasionCell proliferationEsophageal squamous cell carcinomaLong non-coding RNA-HOXA11-AS

Identifiers

PMID41006771
PMCPMC12475127

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.